Application of peripheral blood immune cell typing in predicting the efficacy of immunotherapy for lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049201

Enrollment

Unknown

Registered

2021-07-25

Start date

2021-07-22

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:immunotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histopathologically diagnosed as lung cancer; 2. Imaging assessment is unresectable lung cancer; 3. First-line treatment includes immune monotherapy or immune combination chemotherapy; 4. No other malignant tumors have been diagnosed or treated within 5 years before the diagnosis of lung cancer.

Exclusion criteria

Exclusion criteria: 1. Combined with end-stage liver disease or kidney disease. 2. Long-term use of immunosuppressive drugs.

Design outcomes

Primary

Measure	Time frame
Immune cell subsets;Therapeutic evaluation;	—

Countries

China

Contacts

Public ContactLi Li

Daping Hospital, Army Medical University

lili10119@126.com+86 23 68757780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026